Joe Franklin

Joe Franklin’s practice includes emerging medical technologies, research uses of real world and clinical trial data, and the deployment of artificial intelligence in healthcare and biopharma. He brings experience in both government and the health tech sector to advise clients on the unique challenges and opportunities posed by evolving regulatory frameworks for novel technologies.

Joe was at Verily, Alphabet’s precision health company, from 2021-2024, where his roles included Chief Counsel for Regulatory and Strategic Affairs.

During his years of federal service, Joe held several senior policy roles at FDA, including as policy director for FDA Principal Deputy Commissioner Amy Abernethy. At FDA, Joe played a central role in the Agency’s technology and data modernization strategy and had responsibilities for a broad portfolio of regulatory and scientific programs. While in FDA’s Center for Drug Evaluation and Research (CDER), Joe built and led the biosimilars policy staff in the Office of New Drugs (OND). Joe was FDA’s Deputy Chief of Staff in 2015.

While serving in FDA’s Office of the Chief Counsel, Joe advised CDER and the Office of the Commissioner on biosimilars, emergency use authorizations, user fees, and controlled substances, among other issues. During the COVID-19 pandemic, Joe worked within the HHS General Counsel’s Immediate Office to advise on the federal response.